ArticleCurrent topics in behavioral neurosciences
Neurophysiological biomarkers informing the clinical neuroscience of schizophrenia: mismatch negativity and prepulse inhibition of startle.
Article in Current topics in behavioral neurosciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02634684 (Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis
Who cites it
18 citing papers in PubMed.
- Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Trial
- Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Trial
- Effects of transcranial direct current stimulation on the auditory mismatch negativity response and working memory performance in schizophrenia: a pilot study.Journal of neural transmission (Vienna, Austria : 1996) · 2017Trial
- Prepulse inhibition of the blink reflex in functional neurological disorder and fibromyalgia.Brain : a journal of neurology · 2026Article
- Altered functional connectivity related to prepulse inhibition in functional movement disorder.NeuroImage. Clinical · 2026Article
- Early disruptions in vitamin D receptor signaling induces persistent developmental behavior deficits in zebrafish larvae.PloS one · 2025Article
- Prospective longitudinal assessment of sensorimotor gating as a risk/resiliency factor for posttraumatic stress disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- Receptor-Mediated AKT/PI3K Signalling and Behavioural Alterations in Zebrafish Larvae Reveal Association between Schizophrenia and Opioid Use Disorder.International journal of molecular sciences · 2022Article
- Mismatch Negativity is a Sensitive and Predictive Biomarker of Perceptual Learning During Auditory Cognitive Training in Schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Article
- Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients.Schizophrenia bulletin · 2017Article
- Measuring the capacity for auditory system plasticity: An examination of performance gains during initial exposure to auditory-targeted cognitive training in schizophrenia.Schizophrenia research · 2016Article
- Reduced Prepulse Inhibition as a Biomarker of Schizophrenia.Frontiers in behavioral neuroscience · 2016Article
- Physical Exercise Alleviates Health Defects, Symptoms, and Biomarkers in Schizophrenia Spectrum Disorder.Neurotoxicity research · 2015Review
- Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia.Annals of the New York Academy of Sciences · 2015Review
- Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: characterization of demographic, clinical, cognitive, and functional correlates in COGS-2.Schizophrenia research · 2015Article
- Developing treatments for cognitive deficits in schizophrenia: the challenge of translation.Journal of psychopharmacology (Oxford, England) · 2015Review
- The auditory brain-stem response to complex sounds: a potential biomarker for guiding treatment of psychosis.Frontiers in psychiatry · 2014Article
- Different levels of prepulse inhibition among patients with first-episode schizophrenia, bipolar disorder and major depressive disorder.Journal of psychiatry & neuroscience : JPNArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
With the growing recognition of the heterogeneity of major brain disorders, and particularly the schizophrenias (SZ), biomarkers are being sought that parse patient groups in ways that can be used to predict treatment response, prognosis, and pathophysiology. A primary focus to date has been to identify biomarkers that predict damage or dysfunction within brain systems in SZ patients, that could then serve as targets for interventions designed to "undo" the causative pathology. After almost 50 years as the predominant strategy for developing SZ therapeutics, evidence supporting the value of this "find what's broke and fix it" approach is lacking. Here, we suggest an alternative strategy of using biomarkers to identify evidence of spared neural and cognitive function in SZ patients, and matching these residual neural assets with therapies toward which they can be applied. We describe ways to extract and interpret evidence of "spared function," using neurocognitive, and neurophysiological measures, and, suggest that further evidence of available neuroplasticity might be gleaned from studies in which the response to drug challenges and "practice effects" are measured. Finally, we discuss examples in which "better" (more normal) performance in specific neurophysiological measures predict a positive response to a neurocognitive task or therapeutic intervention. We believe that our field stands to gain tremendous therapeutic leverage by focusing less on what is "wrong" with our patients, and instead, focusing more on what is "right".
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.